stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Revenue
Grifols, S.A.'s revenue for fiscal 2025 was $8.5B, up 9.07% from $7.8B in fiscal 2024. Over the twelve months to 30 September 2026 it was $8.8B. Over the past ten years it has ranged from $4.4B (fiscal 2015) to $8.5B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. Grifols, S.A. ranks 15th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $8.5B | 9.07% |
| FY2024 | $7.8B | 9.39% |
| FY2023 | $7.1B | 11.67% |
| FY2022 | $6.4B | 9.47% |
| FY2021 | $5.8B | (4.32%) |
| FY2020 | $6.1B | 6.82% |
| FY2019 | $5.7B | 7.77% |
| FY2018 | $5.3B | 8.57% |
| FY2017 | $4.9B | 8.91% |
| FY2016 | $4.5B | 2.58% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $2.3B | 18.01% |
| Mar 2026 | $2.0B | (13.64%) |
| Dec 2025 | $2.3B | 5.67% |
| Sep 2025 | $2.2B | 1.57% |
| 29 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| SNY Sanofi compare | $59.1B |
| NVO Novo Nordisk A/S compare | $51.9B |
| BMY Bristol Myers Squibb Company compare | $50.0B |
| GSK GSK PLC Sponsored ADR compare | $44.9B |
| BIIB Biogen Inc. compare | $10.3B |
| GRFS Grifols, S.A. | $8.8B |
| OGN Organon & Co. compare | $6.1B |
| AMRN Amarin Corporation PLC compare | $176.1M |
| NSRX Nasus Pharma Ltd. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on GRFS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement